

## Fundamentals of Biostatistics and Clinical Trial Design Workshop, 2022 Edition

### Faculty and Reviewer Disclosures

#### Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Integrity and Independence in Accredited Continuing Education, ACCP requires that all individuals involved in the development of activity content disclose all financial relationships with ineligible companies in any amount occurring in the last 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. ACCP is required to disclose to the learner the existence of any relationship with an ineligible company that is relevant to the educational content of the activity. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ACCP educational activities are qualified and selected by ACCP and are required to disclose any financial relationships with ineligible companies. ACCP identifies and mitigates conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

- Dr. Larry Segars: Speaker, Ascendis Pharmaceuticals, Inc.
- Dr. Sarah Anderson: Stock, Abbott Laboratories, Becton Dickinson, Johnson & Johnson, Merck

All other planners, presenters, reviewers, ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.